Prognostic value of urokinase plasminogen activator in primary breast carcinoma: Comparison of two immunoassay methods

British Journal of Cancer

Volumn 77, Issue 9, 1998, Pages 1495-1501

  Bouchet, C ^a   Spyratos, F ^a   Hacene K ^a   Durcos, L ^a   Becette V ^a   Oglobine, J ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast cancer; Luminometric immunoassay; Prognosis; Urokinase plasminogen activator

Indexed keywords

ANTIGEN; ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR; PROGESTERONE RECEPTOR; UROKINASE;

ADULT; AGED; ARTICLE; AUTOANALYSIS; BREAST CARCINOMA; CANCER RECURRENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; LUMINESCENCE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031918128     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.246     Document Type: Article

References (36)

1. Benraad THJ, Gerts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJTM, De Witte JH, Foekens JA, Leake RE, Brunner N and Sweep CGI (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA); report of an EORTC/BIOMED-1 Workshop. Eur J Cancer 32A; 1371-1381
2. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of measurement. Lancet 8: 307-310
3. Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377
4. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
5. Bouchet C, Spyratos F, Andrieu C, Deytieux S, Becette V and Oglobine J (1996) Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res Treat 41: 141-146
6. Cho JY, Chung HC, Noh SH, Roh JK, Min JS and Kim BS (1997) High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79: 878-883
7. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34: 187-220
8. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen PI, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266
9. Duffy MJ (1987) Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23: 583-589
10. Duffy MJ, O'Grady P, Devancy D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast cancer. Preliminary report. Cancer 62: 531-533
11. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P (1990) Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
12. EORTC Breast Co-operative Group (1980) Revision of the standards for the assessment of hormone receptor in human breast cancer. Report of the second EORTC workshop, held on 16-17 March 1979, in Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515
13. Fernö M, Borg A, Killander D, Hirschberg L and Brundell J (1994) Urokinase plasminogen activator as prognostic factor in breast cancer: measured with a novel immunoluminometric assay suited for routine use. Breast Cancer Res Treat suppl. 32: 30
14. Fern̈ M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olosson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801
15. Foekens JS, Schmitt M, Pache L, Van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
16. Foekens JS, Buessecker F, Peters HA, Krainick U, Van Putten WLJ, Look MP, Klijn JGM and Kramer MD (1995) Plasminogen activator inhibitor-2 prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427
17. Ganesh S, Sier CFM, Griffioen G, Vloedgraven H, De Boer A, Welvaart K, Van de Velde C, Van Krieken J, Verheijen J, Lamer C and Verspaget HW (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071
18. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y and Sumiyoshi A (1992) The content of urokinase-type plasminogen activator as a prognostic factor in bladder cancer. Int J Cancer 50: 871-873
19. Hilsenbeck SG and Clark GM (1996) Practical p-value adjustment for optimally selected cutpoints. Stat Med 5: 103-112
20. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gossner W and Graeff H (1990) Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
21. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 3: 303-312
22. Jünicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 234: 195-208
23. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530
24. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
25. Kuhn W, Pache L, Schmalfeldt S, Dettmar P, Schmitt M, Jänicke F and Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum based chemotherapy. Gynecol Oncol 55: 401-409
26. Kute T, Gøndahl-Hansen J. Russel G, Christensen IJ and Brünner N (1994) Urokinase-type-plasminogen activator, its inhibitor and cathepsin D predicts prognosis in node negative breast cancer. Proc Am Assoc Cancer Res 35: 201
27. Le Doussal V, Tubiana-Hulin M, Hacene K, Friedman S and Brunet M (1989) Nuclear characteristics as indicators of prognosis in node-negative breast cancer patients. Breast Cancer Res Treat 14: 207-216
28. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907
29. Oka T, Ishida T, Nishino T and Sugimachi K (1991) Immunohistochemical evidence of urokinase plasminogen activator in primary and metastatic tumours of pulmonary carcinoma. Cancer Res 51: 3522-3525
30. Peto R, Pike MC and Armitage P (1977). Design and analysis of randomized clinical trials requiring prolonged observations of each patient. Part II. Analyses and examples. Br J Cancer 35: 1-39
31. Romain S, Spyratos F, Lainé-Bidron C, Bouchet C, Guirou O, Martin PM Oglobine J and Magdelénal H (1995) Comparative study of four extraction procedures for urokinase type plasminogen activator and activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 33: 603-608
32. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Danø K and Grøndahl-Hansen J (1995) Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199-207
33. Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N and Graeff H (1991) Biological and clinical relevance of the urokinase type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta 50: 731-741
34. Skelly MM, Mulcahy HE, Connell T, Troy A, Duggan C, Duffy MJ, Sheahan K and O'Donoghue DP (1995) Urokinase-type plasminogen activator (uPA) is independently related to outcome in colorectal cancer. Ir J Med Sci 164 (suppl. 14):2
35. Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272
36. Wiechelman K, Braun R and Fitzpatrick J (1988) Investigation of the bicinchonic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 193: 265-275